Research programme: RECK activators - Oncolys BioPharma

Drug Profile

Research programme: RECK activators - Oncolys BioPharma

Alternative Names: Reversion-inducing-cysteine-rich protein with kazal motifs activators - Oncolys BioPharma

Latest Information Update: 23 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncolys BioPharma
  • Developer Kyoto University; Oncolys BioPharma
  • Class Antineoplastics
  • Mechanism of Action Gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 15 Jun 2016 Early research in Cancer in Japan (unspecified route)
  • 15 Jun 2016 Oncolys BioPharma and Kyoto University agree to develop RECK activators for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top